CCR5Δ32 Genotype Leads to a Th2 Type Directed Immune Response in ESRD Patients by Muntinghe, Friso L. H. et al.
CCR5D32 Genotype Leads to a Th2 Type Directed
Immune Response in ESRD Patients
Friso L. H. Muntinghe
1*, Wayel H. Abdulahad
2, Minke G. Huitema
2, Jeffrey Damman
3, Marc A. Seelen
3,
Simon P. M. Lems
4, Bouke G. Hepkema
4, Gerjan Navis
3, Johanna Westra
2
1Internal Medicine, Vasculair Medicine, University Medical Center Groningen, Groningen, The Netherlands, 2Rheumatology and Clinical Immunology, University Medical
Center Groningen, Groningen, The Netherlands, 3Internal Medicine, Nephrology, University Medical Center Groningen, Groningen, The Netherlands, 4Laboratory
Medicine, Transplantation Immunology, University Medical Center Groningen, Groningen, The Netherlands
Abstract
Background: In patients with end stage renal disease (ESRD) we observed protection from inflammation-associated
mortality in CCR5D32 carriers, leading to CCR5 deficiency, suggesting impact of CCR5D32 on inflammatory processes.
Animal studies have shown that CCR5 deficiency is associated with a more pronounced Th2 type immune response,
suggesting that in human CCR5D32 carriers the immune response may be more Th2 type directed. So, in the present study
we determined the Th1-Th2 type directed immune response in ESRD patients carrying and not carrying the CCR5D32
genetic variant after stimulation.
Methodology/Principal Findings: We tested this hypothesis by determining the levels of IFN-c and IL-4 and the distribution
of Th1, Th2 and Th17 directed circulating CD4+ and CD8+ T cells and regulatory T cells (Tregs) after stimulation in ESRD
patients with (n=10) and without (n=9) the CCR5D32 genotype. The extracellular levels of IFN-c and IL-4 did not differ
between CCR5D32 carriers and non carriers. However, based on their intracellular cytokine profile the percentages IL-4
secreting CD4+ and CD8+ T cells carrying the CCR5D32 genotype were significantly increased (p=0.02, respectively
p=0.02) compared to non carriers, indicating a more Th2 type directed response. Based on their intracellular cytokine
profile the percentages IFN-c and IL-17 secreting T cells did not differ between carriers and non-carriers nor did the
percentage Tregs, indicating that the Th1, Th17 and T regulatory response was not affected by the CCR5D32 genotype.
Conclusions/Significance: This first, functional human study shows a more pronounced Th2 type immune response in
CCR5D32 carriers compared to non carriers. These differences may be involved in the previously observed protection from
inflammation-associated mortality in ESRD patients carrying CCR5D32.
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Introduction
Genetic variability in the chemokine cascades could potentially
influence disease outcomes by modifying inflammatory processes.
CC-chemokine receptor 5 (CCR5) is one of the chemokine
receptors. It is expressed on T cells and monocytes and it is
important for recruitment [1,2]. Several polymorphisms have been
described for CCR5. The CCR5D32 genetic variant is located on
the chromosome 3p21 and consists of a 32-basepair deletion in the
open reading frame. It effectively results in functional CCR5
deficiency by absence of CCR5 membrane expression [3]. We
observed protection from inflammation-associated mortality in
carriers of the deletion 32 allele in end stage renal disease (ESRD),
suggesting impact of CCR5D32 on the inflammatory process of
atherosclerosis [4]. Also in other human populations, character-
ized by high cardiovascular risk, the presence of the CCR5D32
genotype has been associated with better outcome [5–8].
In chronic inflammatory processes like atherosclerosis T cells
play an important role. Both CD4+ T cells and to a lesser extent
CD8+ T cells are present in atherosclerotic lesions [9–12]. CD4+
T helper cells can differentiate into three effector lineages based on
their cytokine expression: IFN-c/TNF-a producers (Th1), IL-4
producers (Th2) and IL-17 producers (Th17) [12,13]. In addition,
a small fraction of CD4+ T cells can develop into cells with a
regulatory function (Tregs) that are defined by their co-expression
of high levels of surface CD25 and intracellular transcription
factor forkhead box P3 (FoxP3). These Tregs have the remarkable
ability to suppress the proliferation and effector function of other T
cells [9,12]. As with CD4+ T cells, CD8+ T cells can differentiate
to T cytotoxic (Tc)1 or Tc2 cell subsets, secreting predominantly
Th1 or Th2 cytokines respectively [13].
Atherosclerotic inflammation is regarded as a (partly) Th1
driven condition [12]. The CCR5 receptor is highly expressed T-
lymphocytes, on both CD4+ T and CD8+ T cells [2,11]. In
atherosclerotic mice CCR5 deficiency is associated with a more
pronounced Th2 type immune response and less TNF-a and IFN-
c production hereby counteracting the Th1 directed Th1/Th2
disequilibrium of atherosclerotic inflammation [14–17].
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carriers of the CCR5D32 genotype is more Th2 type directed.
Such differences in response might play a role in the protection
against inflammation-associated mortality in ESRD in carriers of
the CCR5D32 genotype. To test this hypothesis we studied the cell
mediated immune responses in peripheral mononuclear cells
(PBMCs) in ESRD patients. We first determined the extracellular
levels of IFN-c and IL-4 after stimulation of PBMCs, and second
the distribution of Th1, Th2 and Th17 directed circulating CD4+
and CD8+ T cells, based on their intracellular cytokine profile
after stimulation, and the percentage of Tregs in ESRD patients
with and without the CCR5D32 genotype.
Methods
Objectives
The objective of the present study was to determine possible
differences in cell mediated immune response between ESRD
carriers and non carriers of the CCR5D32 genotype. To test this
hypothesis we first determined the IFN-c and IL-4 levels after
stimulation of peripheral mononuclear cells (PBMCs) and secondly
the distribution of Type-1, Type-2 and Type-17 directed
circulating CD4+ and CD8+ T cells, based on their intracellular
cytokine profile, as well as the frequency of FoxP3+ regulatory T
cells.
Participants
Biosamples and data from twenty patients with ESRD were
included in this study. These patients were part of an ESRD
cohort from a single kidney transplant centre in the Netherlands
(University Medical Center Groningen), in whom data and
biosamples were collected prior to kidney transplantation. As part
of a larger genotyping project, all patients were genotyped as
described below. For the current project we randomly selected five
homo- and five heterozygous carriers from the cohort. Ten wild
type patients were matched with carriers according to time of
inclusion, hereby creating similar preservation conditions.
Genotyping
The genotypes were determined with a PCR-based allelic
discrimination assay using primers (Life Technologies) and allele-
specific probes (PE Biosystems) as described previously [18].
Patients were grouped by CCR5 genotype, namely those
homozygous for the major allele (non-carriers) and those with 1
or 2 deletion alleles (carriers). Patients with one or two deletion
alleles were grouped together, as it has been demonstrated that
presence of one deletion allele is sufficient to compromise CCR5
function [3].
Sample preparation and thawing
Heparinized venous blood was obtained from ESRD-patients
who gave their informed consent. PBMCs were separated by
conventional Ficoll gradient and frozen in 10% DMSO in FCS
and stored in liquid nitrogen. PBMCs were thawed and washed
twice with RPMI 1640 media (Cambrex Bio Science, Verviers,
Belgium), supplemented with 10% heat inactivated fetal calf serum
and 50 mg/mL gentamycin (Gibco, Scotland, UK).
Determination of extracellular cytokine by ELISA
Thawed PBMCs were cultured in a 5 mL polypropylene tubes
(BD Biosciences) at 2,5610
6 cells/mL per tube, and stimulated
with 40 nM phorbol myristate acetate (PMA; Sigma-Aldrich,
Steinheim, Germany) and 2 nM calcium ionophore (Sigma-
Aldrich). Culture supernatants were collected over a period of
24 hours to determine the extracellular levels of IFN-c, and IL-4
cytokines.
Cytokine levels of IFN-c and IL-4 were measured by
commercial sandwich enzyme linked immunoassay (ELISA) kits
(Pelikine Compact, Sanquin, Amsterdam, The Netherlands),
according to the instructions of the manufacturer.
Determination of intracellular cytokine by flow cytometry
The following conjugated antibodies were used in flow
cytometry: allophycocyanin (APC)–Cy7–conjugated anti-CD69,
peridin-chlorophyll protein (PerCP)–conjugated anti-CD8, phyco-
erythrin (PE)– Cy7–conjugated anti–IL-4, and Alexa Fluor 700–
conjugated anti-IFN-c (all from Becton & Dickinson, Amsterdam,
The Netherlands). Alexa Fluor 488–conjugated anti–IL-17, Alexa
Fluor 647-conjugated anti-TNF-a, and eFluor605
TM–conjugated
anti-CD3 were obtained from eBioscience (San Diego, CA). To
determine the frequency of T cell subsets by measuring
intracellular cytokine production, cells were stimulated for 4 hours
with 40 nM PMA and 2 nM calcium ionophore. Brefeldin A
(10 mg/mL) was added to inhibit cytokine release. After stimula-
tion, cells were washed in wash buffer (phosphate buffered saline,
5% fetal bovine serum, 0.1% sodium azide; Merck, Darmstadt,
Germany) and stained with eFluor 605-conjugated anti-CD3,
PerCP–conjugated anti-CD8 and APC-Cy7–conjugated anti-
CD69 for 15 minutes at room temperature. Cells were fixed with
100 ml Reagent A (Caltag, An Der Grab, Austria) for 15 minutes.
After washing, the pellet was resuspended in 100 ml permeabiliza-
tion Reagent B (Caltag) and labeled with PE-Cy7–conjugated
anti–IL-4, Alexa Fluor 700–conjugated anti-IFN-c, Alexa Fluor
647-conjugated anti-TNF-a, Alexa Fluor 488–conjugated anti–IL-
17, and APC-Cy7–conjugated anti-CD69 for 30 minutes in the
dark. After staining, the cells were washed and immediately
analyzed on a FACS-LSRII flow cytometer (Becton Dickinson).
Seven-color flow cytometric acquisition was performed using
FACSDiva software (Becton Dickinson). For all flow cytometry
analyses, data were collected for 2610
5 cells and plotted using the
Win-List software package (Verity Software House, Topsham,
ME). Because stimulation reduces surface expression of CD4 on T
cells, CD4 T cells were identified indirectly by gating on CD3+
and CD82 lymphocytes, whereas CD8+ T cells were identified by
directly gating on CD3+ and CD8+ lymphocytes. Subsets of
activated CD4+ and CD8+ T cells in response to mitogenic
stimulation were evaluated by double expression of activation
marker CD69 and intracellular cytokine production of IFN-c (for
type-1) or IL-17 (for type-17) or IL-4 (for type-2). The
unstimulated samples were used as a guide for setting the linear
gates to delineate positive and negative populations.
Determination of regulatory T cell frequencies
PBMCs were washed with cold PBS (pH 7.2) and incubated
with appropriate concentrations of PerCP-conjugated anti-CD4,
FITC-conjugated anti-CD3 and PE-conjugated anti-CD25 (all
purchased from BD) for 30 min at 4uC in the dark. Cells were
then washed with cold PBS, followed by fixation and permeabi-
lization in Fix/Perm buffer (FoxP3 staining kit, eBioscience,
Uithoorn, The Netherlands) for 45 min at 4uC. Subsequently, cells
were washed with cold permeabilization buffer (FoxP3 staining kit,
eBioscience, Uithoorn, The Netherlands). To block nonspecific
binding, normal rat serum was added for 10 min, followed by the
addition of APC-conjugated rat anti-human FoxP3 (eBioscience,
Uithoorn, The Netherlands). After incubation for 30 min at 4uC,
the cell suspension was washed twice with cold permeabilization
buffer, and immediately analyzed on FACS-Calibur (BD). Data
were collected for 2610
5 cells and plotted using the Win-List
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Positively and negatively stained populations were calculated by
quadrant dot-plot analysis, determined by the isotype matched
control antibodies of irrelevant specificity (obtained from BD and
eBioscience).
Ethics
All patients gave written informed consent and the local medical
ethics committee from the University Medical Center Groningen
(METc UMC Groningen), the Netherlands, gave their approval.
Statistical methods
Patients were grouped by CCR5 genotype, namely those
homozygous for the major allele (non-carriers) and those with 1
or 2 deletion alleles (carriers). The latter were grouped together, as
it has been demonstrated that presence of one deletion allele is
sufficient to compromise CCR5 function [3]. Data are presented
as the median. The nonparametric Mann-Whitney U test was
used to compare data from patients with and without the
CCR5D32 genotype. Differences were considered statistically
significant at 2-sided p values less than 0.05.
Results
Patients
From the 20 patients who were included in this study 1
stimulation test failed due to the fact that the T cells could not be
stimulated. Further statistical analyses were performed on the
remaining 19 patients. Baseline characteristics are shown in
Table 1. There were no statistically significant differences in
baseline characteristics between the 2 genotype groups.
Extracellular cytokines of type-1 and type-2 T cells
To assess the functional capacity of the responding PBMCs the
total amount of IFN-c and IL-4 after stimulation was determined.
As shown in Figure 1, the levels of extracellular IFN-c and IL-4
were not statistically significant different between carriers and non
carriers of the CCR5D32 genotype.
Intracellular cytokines of type-1, type-2, and type-17 T
cells
To elucidate the functional phenotype of the CD4+ and CD8+
T cells responding to stimulation, activated T cells were gated and
evaluated for expression of the activation marker CD69 versus
intracellular expression of the cytokines IFN-c, IL-17 and IL-4.
The results are shown in Figure 2 and 3. The percentages IL-4
secreting CD4+ and CD8+ T cells from patients with the
CCR5D32 genotype was significantly (p=0.02, respectively
p=0.02) increased compared to patients not carrying the
CCR5D32 genotype, indicating a more Th2 type directed
response. The percentages IFN-c secreting CD4+ and CD8+ T
cells did not significantly differ between carriers and non carriers
of CCR5D32, meaning the Th1 and Th17 response did not differ
between these 2 groups. Comparing the CCR5D32 homozygous
and heterozygous CD4+ and CD8+ T cells showed no significant
differences.
Frequencies of regulatory T cells
To address the question whether differences in Tregs frequen-
cies influence the distribution of T cell subsets between CCR5D32
carriers and non carriers, FoxP3+CD25
HighCD4
+ T cells were
analyzed in both groups. No significant differences were found
between the 2 genotype groups (Figure 4). It seems, therefore, that
Table 1. Baseline characteristics.
CCR5 wild
type
(n=9)
CCR5 deletion
32
(n=10)
Gender; male 4 (44.4) 7 (70.0)
Age (year) 51 (14) 51 (13)
Primary kidney disease
Renal vascular disease and
hypertension
33
Diabetes mellitus 1 0
Cystic kidney disease 1 3
Pyelonephritis 1 1
Primary oxalosis 1 0
Unknown 2 3
Dialysis duration (days) 1570 (880) 1005 (734)
Hemodialysis 5 (55.6) 4 (44.4)
Body Mass Index 26 (4.94) 25 (3.21)
Systolic bloodpressure (mmHg) 147 (19) 138 (10)
Diastolic bloodpressure (mmHg) 86 (8) 86 (9)
Data are presented as number (percentage), mean (SD).
doi:10.1371/journal.pone.0031257.t001
Figure 1. IFN-c and IL-4 ELISA per 2,5610
6 PBMCs in carriers
and non carriers of the CCR5D32 genotype. Levels of IFN-c and IL-
4 after stimulation from carriers (n=10) and non carriers (n=9) are
shown. Horizontal lines represent the medians.
doi:10.1371/journal.pone.0031257.g001
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between CCR5D32 carriers and non carriers.
Discussion
In the present study we demonstrate a skewing of circulating
CD4+ and CD8+ T cells towards the Th2 phenotype based on
their intracellular cytokine profile after stimulation in ESRD
patients carrying the CCR5D32 genotype. These data are in line
with animal data showing that genetic deficiency of CCR5 results
in a shift in immune response towards a Th2 type response, and
support the assumption that genetic differences in immune
response are involved in the protection against inflammation-
associated mortality in ESRD patients reported previously [4].
In ESRD patients cardiovascular disease is a main cause of
premature deaths [19]. Chronic inflammation is a major
contributing factor [20,21]. The inflammatory nature of the
process of atherosclerosis is nowadays well recognized [22]. In this
process T cells play an important role [9–12]. Th1 cells, which
produce IFN-c as the principal cytokine, are thought to be pro-
inflammatory and pro-atherogenic and are the most prevalent
subtype in atherosclerotic lesions; Th2 cells, with IL-4 as the major
cytokine, have the ability to inhibit Th1 differentiation and could
therefore be anti-atherogenic. The role of Th17 cells, producing
IL-17, in atherosclerosis is not yet clear [23]. So, until now
atherosclerotic inflammation is regarded as a Th1 directed Th1/
Th2 disequilibrium [12].
To our knowledge, this is the first functional study investigating
the Th1/Th2 directed immune response in relation to the
CCR5D32 genetic variant in human. Animal studies consistently
show a more pronounced Th2 immune response during genetic
deficiency of CCR5 or pharmacological CCR5 blockade in
atherosclerotic and other inflammatory conditions. In diet induced
atherosclerotic inflammation in mice, genetic deletion of CCR5
was associated with a more stable plaque phenotype and reduced
Th1 type immune response of stimulated splenocytes and an
increased Th2 type response in splenocytes and lymph node cells
[14]. After wire injury in mice with CCR5 deficiency a more
atheroprotective immune response was seen, i.e. low IFN-c and
elevated IL-10 in CD4+ splenocytes compaired to CCR5 wild type
mice [15]. Also in genetically CCR5 deficient mice with diet
induced atherosclerosis, reduced lesion size, increased IL-10 and
decreased TNF-a production by CD4+ and CD8+ T cells [16],
and reduced macrophage accumulation in plaques and lowered
circulating IL-6 levels was seen [17]. In CCR5 deficient mice a
more CD4+ Th2 cell activation pattern was seen in colitis in
contrast to CCR5 wild type mice [24]. Interestingly, in CCR5
genetically deficient mice who received a renal allograft less Th1
Figure 2. Flow cytometric characterization of CD4 and CD8 T cell subsets from CCR5 wild type (left panel) and CCR5 deletion 32
(right panel). PBMCs were stimulated in vitro with PMA and Ca-ionophore for 4 hours in the presence of BFA. The CD4 and CD8 T cell subsets were
then assessed for the expression of activation marker CD69 versus intracellular cytokine (IFN-c, IL-17, and IL-4). The percentage in the upper right
corner of each plot represents the net percentage of positive cells.
doi:10.1371/journal.pone.0031257.g002
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found during chronic intragraft immune response [25]. In an islet
transplantation model it was shown that in genetically CCR5
deficient mice not only in the intragraft immune response but also
in the periphery a Th2 shift occurred [26]. In mice with diet-
induced atherosclerosis treatment with a RANTES chemokine
antagonist, hereby blocking CCR5, reduced atherosclerotic plaque
formation, associated with reduced proliferation and secretion of
Th1 cytokines IFN-c and TNF-a, without difference in Th2
cytokine profile [27]. In rats pharmacological CCR5 blockade in
stimulated endothelial cells inhibited selective transmigration of
CD4+ Th1 cells [28].
Our results extend these animal data on functional differences
in immune response for the first time to a human setting and
support our previous human cross-sectional association study,
showing absence of association between serum CRP and TNF-a
Figure 3. Percentages of IL-4, IL-17 and IFN-c secreting CD4 and CD8+ T cells in carriers and non carriers of the CCR5D32
polymorphism. In the left panel the frequencies of IL-4, IL-17 and IFN-c secreting cells among CD69+, CD4+ T cells from non carriers (n=9) and
carriers (n=10) of the CCR5D32 genotype are shown. In the right panel the frequencies of IL-4, IL-17 and IFN-c secreting cells among CD69+, CD8+ T
cells from non carriers (n=9) and carriers (n=10) of the CCR5D32 polymorphism are shown. Horizontal lines represent the median percentage.
doi:10.1371/journal.pone.0031257.g003
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contrast to patients without this genetic variant, supporting a
reduced Th1 immune response in CCR5D32 [29]. It should be
emphasized that ELISA and flowcytometry methods give different
types of results and that measuring the intracellular cytokine
production by FACS is more accurate than ELISA. The measured
cytokines by ELISA can be released from several cells, whereas
FACS-method identifies the intracellular cytokines produced on a
single-cell level. In addition, difference in T cell numbers between
the study samples may influence the results obtained from ELISA
but not from FACS method hereby probably explaining why we
did not find a difference in extracellular cytokine levels between
CCR5D32 carriers and non carriers. Since Tregs are responsible
for regulation and suppression of T cell responses [9,12], one may
argue that differences in Tregs could underlie the increase in IL-4
expression in CCR5D32 carriers. However, no significant
differences were observed in the percentages of Tregs between
CCR5D32 carriers and non carriers. Thus, the increased Type 2
response in CCR5D32 carriers cannot be related to different
frequencies of Tregs.
Together, these findings provide an explanation for the
previously observed protection from inflammation-related mortal-
ity in ESRD in CCR5D32 carriers, as they support a less pro-
inflammatory, pro-atherogenic immune response in carriers of the
deletion [4]. Our results could also provide a mechanism
underlying the protection against atherosclerosis by pharmacolog-
ical blockade of the CCR5 pathway in animal studies [30–32]. Of
note, CCR5 blockade has become feasible in humans, and is
currently used for treatment of HIV-infection [33]. It has been
proposed that CCR5 blockade may be a strategy for protection
against inflammation driven cardiovascular disease in ESRD and/
or transplantation [34,35]. Our current results contribute to
understanding of mechanisms that could be affected by CCR5
blocking agents in ESRD.
Limitations
Acknowledged limitation in this study is the relatively small
sample size. Besides this one blood sample failed to be stimulated.
However, as mentioned above, the results are in accordance with
animal data and extend the findings of a correlation study in
ESRD patients, supporting the robustness of our findings. Another
limitation is that we studied ESRD patients only. ESRD as such
affects T-cell properties [36]. Whereas the effects of CCR5
deficiency appear to be remarkably consistent across different
species and inflammatory conditions, nevertheless generalization
of our results to other populations would require a separate study.
In conclusion, we present the first human data on a difference in
Th1/Th2 balance dependent on the CCR5D32 genotype in
ESRD patients. Stimulated CD4+ and CD8+ T cells of patients
with one or two CCR5D32 alleles show an increased Th2 type
phenotype base on their intracellular cytokine profile. Differences
in immune response may be involved in the impact of CCR5D32
on outcome in ESRD, and possible other inflammatory condi-
tions.
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